Abstract
The advent of CRISPR-Cas9 gene-editing technology has sparked a complex discourse on diversity, equity, and inclusion (DEI). While it could potentially eradicate genetic disorders affecting marginalized groups, concerns arise regarding ethical implications, eugenics, exacerbating biases, and socioeconomic divides. One salient aspect of this discourse pertains to the ethical considerations surrounding using CRISPR-Cas9 for germline editing, which could theoretically eradicate genetic disorders disproportionately affecting specific populations. Proponents argue it could foster inclusivity through personalized therapies for underrepresented populations, though met with skepticism. This revolutionary tool necessitates critically examining its ethical, socioeconomic, and governance ramifications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
